Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1148/radiol.2281011651
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dyke, J. P.
Right arrow Articles by Ballon, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dyke, J. P.
Right arrow Articles by Ballon, D.
(Radiology 2003;228:271-278.)
© RSNA, 2003


Technical Developments

Osteogenic and Ewing Sarcomas: Estimation of Necrotic Fraction during Induction Chemotherapy with Dynamic Contrast-enhanced MR Imaging1

Jonathan P. Dyke, PhD, David M. Panicek, MD, John H. Healey, MD, Paul A. Meyers, MD, Andrew G. Huvos, MD, Lawrence H. Schwartz, MD, Howard T. Thaler, PhD, Paul S. Tofts, DPhil, Richard Gorlick, MD, Jason A. Koutcher, MD, PhD and Douglas Ballon, PhD

1 From the Department of Radiology (J.P.D., D.M.P, L.H.S., D.B.), Weill Medical College of Cornell University, 1300 York Ave, Box 234, New York, NY 10021-4885; Departments of Radiology (D.M.P., L.H.S., J.A.K., D.B.), Surgery (J.H.H.), Pediatrics (P.A.M., R.G.), Pathology (A.G.H.), Biostatistics (H.T.T.), Medical Physics (J.A.K., D.B.), and Medicine (J.A.K.), Memorial Sloan-Kettering Cancer Center, New York, NY; and Institute of Neurology, University College London, England (P.S.T.). Received October 9, 2001; revision requested January 2, 2002; final revision received October 16; accepted November 6. Supported in part by National Institutes of Health grants R01HL50139, CA05826-038A1, and RO1CA62556. Address correspondence to J.P.D. (e-mail: jpd2001@med.cornell.edu).

Dynamic contrast material–enhanced magnetic resonance (MR) images of primary osteogenic sarcoma (n = 19) and Ewing sarcoma (n = 10) were reviewed in 29 patients undergoing induction chemotherapy before surgery. Histogram distributions containing the initial slope and pharmacokinetic model parameters from individual voxels within each tumor were fitted for each patient. The histogram analysis of initial slope from the tumor correlated well with percentage necrosis as determined at pathologic examination (r = 0.60, P < .001), as did a two-compartment pharmacokinetic model (r = 0.64, P < .001). Both methods predicted tumors with clinically important degrees of necrosis (ie, ≥90%) in a large majority of cases. The ability to determine response to induction chemotherapy by means of noninvasive monitoring of necrotic fraction with perfusion MR imaging methods may provide useful prognostic information and help surgical planning.

© RSNA, 2003

Index terms: Bone neoplasms, MR, 41.12143, 44.12143, 45.12143 • Chemotherapy, 41.3221, 41.3281, 44.3221, 44.3281, 45.3221, 45.3281 • Ewing sarcoma, 41.3281, 44.3281, 45.3281 • Osteosarcoma, 41.3221, 44.3221, 45.3221




This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
M. S. Kim, S.-Y. Lee, W. H. Cho, W. S. Song, J.-S. Koh, J. A. Lee, J. Y. Yoo, and D.-G. Jeon
Tumor Necrosis Rate Adjusted by Tumor Volume Change Is a Better Predictor of Survival of Localized Osteosarcoma Patients
Ann. Surg. Oncol., March 1, 2008; 15(3): 906 - 914.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Muruganandham, M. Lupu, J. P. Dyke, C. Matei, M. Linn, K. Packman, K. Kolinsky, B. Higgins, and J. A. Koutcher
Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.
Mol. Cancer Ther., August 1, 2006; 5(8): 1950 - 1957.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
H. C. Thoeny, F. De Keyzer, V. Vandecaveye, F. Chen, X. Sun, H. Bosmans, R. Hermans, E. K. Verbeken, C. Boesch, G. Marchal, et al.
Effect of Vascular Targeting Agent in Rat Tumor Model: Dynamic Contrast-enhanced versus Diffusion-weighted MR Imaging
Radiology, November 1, 2005; 237(2): 492 - 499.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
M. van Vliet, C. F. van Dijke, P. A. Wielopolski, T. L. M. ten Hagen, J. F. Veenland, A. Preda, A. J. Loeve, A. M. M. Eggermont, and G. P. Krestin
MR Angiography of Tumor-related Vasculature: From the Clinic to the Micro-environment
RadioGraphics, October 1, 2005; 25(suppl_1): S85 - S97.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2003 by the Radiological Society of North America.